There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adamis Pharma (NASDAQ:ADMP) and TG Therapeutics (NASDAQ:TGTX) with bullish sentiments.
Adamis Pharma (ADMP)
In a report issued on August 10, Andrew D’silva from B.Riley FBR reiterated a Buy rating on Adamis Pharma, with a price target of $7.50. The company’s shares opened today at $3.25.
D’silva commented:
“Adamis Pharmaceuticals (ADMP) filed its 10-Q for 2Q18 AMC on 8/9 and its earnings PR was released BMO, 8/10. ADMP doesn’t host a conference call. Its 2Q18 top-line/EPS came in at $3.9M/($0.29), compared to our/consensus estimates of $3.8M/($0.22) and $4.0M/($0.19), respectively. The EPS miss was primarily due to higher R&D, as ADMP continues to advance its pipeline and likely began spending on its sublingual tadalafil candidate for erectile dysfunction during the period, which was only recently disclosed.”
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 26.9% and a 53.8% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Oramed Pharmaceuticals, and Sorrento Therapeutics.
Adamis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $9.75, implying a 200.0% upside from current levels. In a report issued on August 10, Maxim Group also maintained a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
TG Therapeutics (TGTX)
B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on TG Therapeutics today and set a price target of $25. The company’s shares opened today at $11.85.
Kumar said:
“Tuesday after the market close, August 7, 2018, TG Therapeutics (TGTX) announced 2Q18 earnings and provided a corporate update. We have reasonable conviction for success for the firm’s lead asset combination, anti-CD20 monoclonal antibody (mAb) ublituximab and PI3Kδ inhibitor umbralisib (hereafter known as “U2”), in the end of summer 2018 objective response rate (ORR) readout from the Phase III UNITY-CLL trial of U2 versus Gazyva and chlorambucil (hereafter known as “GC”) across all lines of chronic lymphocytic leukemia (CLL). After 2Q18 model updates, we reiterate our TGTX Buy rating, $25 price target, and TG Therapeutics’ status as one of our Out-the-Gate 2018 picks.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.2% and a 52.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
Currently, the analyst consensus on TG Therapeutics is a Strong Buy with an average price target of $28.33, which is a 139.1% upside from current levels. In a report issued on August 8, H.C. Wainwright also assigned a Buy rating to the stock with a $38 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
